Literature DB >> 6275997

Clinical experience in the diagnosis and treatment of infections in the compromised host.

L A Cone, D Woodard, N A Helm.   

Abstract

A number of disorders of host resistance to infections occur in cancer patients. Defects in granulocytes, complement synthesis and antibody formation, cellular immunity, and mucocutaneous boundaries are discussed. Most infections in these compromised patients are caused by a few gram-negative rods and gram-positive cocci, although other bacteria, opportunistic fungi, intracellular parasites, and DNA viruses also cause severe disease. Cefotaxime was found to be an effective antimicrobial in the treatment of 40 cancer patients with infections of the urinary or lower respiratory tracts, bacteremia, soft-tissue infections, and fever of undetermined origin. Cefotaxime in combination with ticarcillin or an aminoglycoside may improve response in infections due to opportunistic organisms such as Pseudomonas.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6275997

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  2 in total

Review 1.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

2.  Clostridium difficile induced colitis occurring during cefotaxime therapy.

Authors:  S T Green; R Mackie; H McMillan; J W Davie
Journal:  Ulster Med J       Date:  1985-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.